ErbB2 pathway activation upon Smad4 loss promotes lung tumor growth and metastasis

Liu, J., Cho, S. N., Akkanti, B., Jin, N., Mao, J., Long, W., ... & Creighton, C. J.

Cell reports10.9 (2015): 1599-1613.

Lung cancer remains the leading cause of cancer death. Genome sequencing of lung tumors from patients with squamous cell carcinoma has identified SMAD4 to be frequently mutated. Here, we use a mouse model to determine the molecular mechanisms by which Smad4 loss leads to lung cancer progression. Mice with ablation of Pten and Smad4 in airway epithelium develop metastatic adenosquamous tumors. Comparative transcriptomic and in vivo cistromic analyses determine that loss of PTEN and SMAD4 results in ELF3 and ErbB2 pathway activation due to decreased expression of ERRFI1, a negative regulator of ERBB2 in mouse and human cells. The combinatorial inhibition of ErbB2 and Akt signaling attenuate tumor progression and cell invasion, respectively. Expression profile analysis of human lung tumors substantiated the importance of the ErbB2/Akt/ELF3 signaling pathway as both a prognostic biomarker and a therapeutic drug target for treating lung cancer.

ErbB2-pathway-activation-upon-Smad4-loss-promotes-lung-tumor-growth-and-metastasis

Products Used in this Publication

Catalog NumberCASProduct NamePrice
B0084-061382180288-69-1TrastuzumabInquiry

Related Products

Catalog NumberCASProduct NamePrice
B0084-1702551035638-91-5PF 6274484Inquiry
B0084-4213841050500-29-2AST-1306Inquiry
B0084-4524731110813-31-4DacomitinibInquiry
B0084-4621511092364-38-9PoziotinibInquiry
B0084-4743281058156-90-3AnlotinibInquiry